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Correction
After publication of our article [1] we noted that in Table 1 
for Prothrombinex-VF ‘Antithrombin and heparin added’ 
should have been included under the ‘Additional infor-
mation’ column. A copy of the table with the correct 
infor mation can be found overleaf.
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Table 1. Composition of PCCs in the World Federation of Hemophilia register of clotting factor concentrates
 International units relative to factor IX
  Factor Factor Factor Factor  Additional
Brand name Manufacturer II VII IX X Viral inactivation information
Bebulin VH Baxter BioScience,  120 (13) 100 100 Vapour heat, 60°C for 10 hours at 190 mbar, Heparin added
 Austria      then 80°C for 1 hour at 375 mbar
Beriplex P/N CSL Behring,  128 68 100 152 Pasteurisation at 60°C for 10 hours, and  Protein C; 
 Germany     nanofi ltration antithrombin, heparin 
       and albumin added
Cofact Sanquin,  56-140 28-80 100 56-140 Solvent/detergent and 15 nm Antithrombin added
 the Netherlands     nanofi ltration
KASKADIL LFB, France 148 40 100 160 Solvent/detergent Heparin added
Octaplex Octapharma, Austria  44-152 36-96 100 50 Solvent/detergent and nanofi ltration Heparin added; low
 and France       activated factor VII 
       content
Profi lnine SD Grifols, USA 148 (11) 100 64 Solvent/detergent –
Prothrombinex VF CSL Bioplasma,  100 (–) 100 100 Dry heat, 80°C for 72 hours and Antithrombin and
 Australia     nanofi ltration heparin added
Prothromplex T Baxter BioScience,  100 85 100 100 Vapour heat, 60°C for 10 hours at 190 mbar, Antithrombin and
 Austria      then 80°C for 1 hour at 375 mbar heparin added
UMAN Complex D.I. Kedrion, Italy 100 (–) 100 80 Solvent/detergent and dry heat, 100°C for  Antithrombin and
      30 minutes heparin added
Composition of prothrombin complex concentrates (PCCs) listed in the World Federation of Hemophilia register of clotting factor concentrates [54], excluding 
concentrates for national markets only or for which the concentrations of factors relative to factor IX were not available from the relevant product information sheets. 
Factor VII presented in parentheses for three-factor PCCs.
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